Fortress Biotech, Inc. filings document a biopharmaceutical issuer with common stock and 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock listed on the Nasdaq Capital Market. Its SEC record includes Form 8-K reports on operating results, FDA approvals, priority review voucher monetization, credit agreement amendments and subsidiary capital actions.
Proxy materials describe annual meeting matters, board governance, executive compensation and equity awards. Registration statements and material-event filings add disclosure on securities offerings, capital structure, risk factors, material agreements and ownership interests in portfolio companies such as Cyprium Therapeutics and Journey Medical.
Fortress Biotech, Inc. (FBIO) repaid in full the remaining $15.0 million in principal under its Oaktree Agreement on September 30, 2026. It also paid approximately $435,000 in accrued interest, a $150,000 prepayment fee and other closing costs.
Following repayment, all indebtedness under the agreement was satisfied and paid in full, all liens and other security interests securing it were released and terminated, and the agreement automatically terminated pursuant to its terms.
Fortress Biotech, Inc. Chief Financial Officer David Jin acquired 1,190 shares of common stock at $1.819 per share on October 1, 2026, under the company's Employee Stock Purchase Plan. The acquisition was voluntarily reported and was exempt under Rule 16b-3(d) and Rule 16b-3(c); no Rule 10b5-1 plan is reported. His reported holdings after the acquisition were 1,652,761 shares, including 1,230,000 shares underlying deferred restricted stock units and 400,000 shares underlying restricted stock units.
Fortress Biotech, Inc. (FBIO) is the subject of a Schedule 13G filed by Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander reporting passive beneficial ownership of Fortress Biotech common stock. The reporting group discloses beneficial ownership of up to 1,778,561 shares of common stock, representing 5.3% of the class, held with shared voting and dispositive power and no sole voting or dispositive power. The filing states that the securities are held by entities over which Millennium Management LLC and related entities have voting control and investment discretion, and it notes that this structure should not itself be construed as an admission of beneficial ownership by Millennium Management LLC, Millennium Group Management LLC, or Mr. Englander.
Fortress Biotech, Inc. reported consolidated net income of $137.8 million for the six months ended June 30, 2026, driven primarily by a $158.9 million gain on the sale of a Rare Pediatric Disease priority review voucher at subsidiary Cyprium. Net revenue for the period was $34.8 million, while total operating expenses of $52.5 million produced a loss from operations of $17.7 million, indicating that core operations remain unprofitable.
Cash and cash equivalents rose to $196.6 million at June 30, 2026 from $79.4 million at year-end 2025, supported by $144.6 million of net cash provided by operating activities. Total assets increased to $316.7 million, and total stockholders’ equity to $206.1 million, partly reflecting the Cyprium dividend and fair value gains on equity investments. Notes payable, net, declined to $39.6 million, and the company was in compliance with covenants under both the Oaktree and SWK credit facilities.
Management states that $153.8 million of cash and cash equivalents at the parent entity level is considered sufficient to fund operations for at least twelve months after the report date, though additional capital may be needed for development programs and strategic growth. Dividends on the 9.375% Series A preferred stock remain paused and cumulative undeclared dividends totaled about $16.0 million as of June 30, 2026.
Fortress Biotech, Inc. reported second-quarter 2026 net revenue of $18.7 million, a 14% increase over the same quarter in 2025. Product revenue reached $17.8 million, and total net revenue for the first six months of 2026 was $34.8 million, up from $29.6 million a year earlier.
Despite higher revenue, the quarter showed a net loss attributable to common stockholders of $2.5 million, compared with net income of $13.4 million in the prior-year quarter. For the first half of 2026, net income attributable to common stockholders was $105.9 million, driven largely by a $158.9 million gain from the sale of a priority review voucher and other investment-related items.
The balance sheet strengthened notably: cash and cash equivalents were $196.6 million as of June 30, 2026, up from $79.4 million at year-end 2025. Total assets rose to $316.7 million, while long-term notes payable declined to $34.6 million. Total stockholders’ equity increased to $206.1 million, from $62.2 million at December 31, 2025.
Jin David reported acquisition or exercise transactions in this Form 4 filing.
Fortress Biotech, Inc. Chief Financial Officer Jin David reported receiving an equity compensation grant of 400,000 restricted stock units, each representing one share of common stock. The units vest in four equal annual installments, with the first vesting on January 5, 2027, contingent on his continued service.
After this award, his reported holdings total 1,651,571 shares of common stock, including 1,230,000 shares underlying previously granted deferred restricted stock units. The transaction reflects a grant or award, not an open-market purchase.
Fortress Biotech reported the results of its 2026 annual meeting of stockholders held virtually on June 17. Stockholders voted on electing seven directors to serve until the 2027 meeting and on ratifying KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026.
Each director nominee, including Lindsay A. Rosenwald, Jimmie Harvey Jr., Malcolm Hoenlein, Dov Klein, J. Jay Lobell, Kevin L. Lorenz, and Michael S. Weiss, received more votes "For" than "Against." The proposal to ratify KPMG LLP also received substantially more votes "For" than "Against," based on the reported vote totals.
Highbridge Capital Management amends a Schedule 13G to report beneficial ownership of 2,734,654 shares of Fortress Biotech common stock issuable upon exercise of warrants. The filing states this represents 7.8% of the class based on March 25, 2026 outstanding shares of 32,202,564.
The statement attributes sole voting and dispositive power over the 2,734,654 shares to Highbridge and identifies Highbridge Tactical Credit Master Fund, L.P. as a Highbridge Fund holding more than 5%. The filing is signed by Kirk Rule on May 15, 2026.
Fortress Biotech reported a sharp turnaround to profitability driven by a major asset sale. For the quarter ended March 31, 2026, net revenue rose to $16.0 million, mainly from dermatology product sales at Journey Medical.
The key event was Cyprium’s sale of a Rare Pediatric Disease priority review voucher for $205 million, generating a gain of $158.9 million and lifting net income attributable to common stockholders to $108.4 million, or $3.44 basic EPS. Cash and cash equivalents jumped to $255.8 million, and total assets nearly doubled to $356.9 million, while long-term notes payable, net, declined to $39.4 million after prepayments on the Oaktree facility. Management states that Parent Entity cash of $209.9 million is sufficient to fund operations for at least 12 months, although the company still expects operating losses over the next several years and may pursue additional financings.
Fortress Biotech reported a sharp turnaround in the first quarter of 2026, driven by monetizing a Rare Pediatric Disease Priority Review Voucher for $205 million. This generated a gain on sale of $158.9 million and lifted net income attributable to common stockholders to $108.4 million, or $3.44 basic and $2.82 diluted EPS, compared with a loss a year earlier.
Net revenue rose to $16.0 million, up from $13.1 million, while operating loss narrowed as selling, general and administrative and research and development costs declined. Cash and cash equivalents increased to $255.8 million, and total stockholders’ equity grew to $202.4 million. Management highlighted FDA approval of ZYCUBO for Menkes disease, expected future royalties from ZYCUBO and UNLOXCYT, and debt reduction, including lowering Oaktree principal to $15.0 million, as key steps supporting its diversified portfolio strategy.